PD-1 Inhibitors Combined With Targeted Therapy With or Without Interventional Therapy for Advanced HCC
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This trial is designed to explore the efficacy and safety of interventional therapy combined with PD-1 inhibitors and targeted therapy in the treatment of advanced hepatocellular carcinoma. Eligible participants will be divided into two groups based on their treatment plans: one receiving PD-1 inhibitors combined with targeted therapy, and the other receiving PD-1 inhibitors combined with targeted therapy alongside interventional therapy, which includes C-TACE, D-TACE, and HAIC. The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
Researchers will closely monitor and rigorously evaluate the efficacy and safety of the treatment in participants through follow-up assessments. The primary endpoint is the Objective Response Rate (ORR), while secondary endpoints include Disease Control Rate (DCR), Progression-Free Survival (PFS), Overall Survival (OS), Duration of Response (DoR), Adverse Events (AE), and Serious Adverse Events (SAE).